GlassScriptPhysician profile
Utpal Kumar Bhanja
NPI 1003801689
$4,249.27
in general payments reported to CMS, 2019-2025
49 companies · $475 in 2025
The $475 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $410 · 2021: $723 · 2022: $725 · 2023: $981 · 2024: $424 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,781 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,780.84 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $486.98 | 2019-2025 | |
| Seagen INC. | $301.42 | 2020-2025 | Padcev |
| Amgen INC. | $278.27 | 2019-2023 | Lumakras, Kyprolis |
| Merck Sharp & Dohme LLC | $264.77 | 2019-2024 | Keytruda, Lynparza |
| Myriad Genetic Laboratories, INC. | $237.53 | 2023 | Myrisk |
| Janssen Biotech, INC. | $225.45 | 2019-2024 | Tecvayli, Darzalex, Talvey |
| Pharmacyclics LLC, An Abbvie Company | $223.84 | 2019-2021 | |
| Celgene Corporation | $192.49 | 2021-2025 | Reblozyl |
| Pfizer INC. | $187.47 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $152.11 | 2021-2025 | Opdualag, Opdivo |
| Daiichi Sankyo INC. | $150.55 | 2021-2024 | Injectafer, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $111.15 | 2020-2023 | Iclusig |
| Regeneron Healthcare Solutions, INC. | $91.09 | 2021-2025 | Lynozyfic, Libtayo |
| Astrazeneca Pharmaceuticals LP | $90.43 | 2021-2023 | Lynparza, Imfinzi |
| Incyte Corporation | $88.18 | 2020-2024 | Jakafi |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Utpal Bhanja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.